Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

March 30, 2012

Primary Completion Date

October 23, 2019

Study Completion Date

April 23, 2020

Conditions
Castration-Resistant Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer AJCC v7
Interventions
DRUG

Abiraterone Acetate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Prednisone

Given PO

DRUG

Veliparib

Given PO

Trial Locations (14)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

53715

University of Wisconsin Women's Health Center, Madison

53792

University of Wisconsin Hospital and Clinics, Madison

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

M D Anderson Cancer Center, Houston

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

98195

University of Washington Medical Center, Seattle

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01576172 - Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter